TETRAPHASE PHARMACEUTICALS INC Uncategorized Contracts & Agreements
27 Contracts & Agreements
- Form of Contingent Value Rights Agreement, by and between the Parent and the Rights Agent (Filed With SEC on June 24, 2020)
- Form of Support Agreement, dated June 24, 2020, by and among the Parent, the Purchaser and the stockholder named therein (Filed With SEC on June 24, 2020)
- Form of Contingent Value Rights Agreement, by and between the Parent and the Rights Agent (Filed With SEC on June 4, 2020)
- Form of Support Agreement, dated June 4, 2020, by and among the Parent, the Purchaser and the stockholder named therein (Filed With SEC on June 4, 2020)
- Form of Contingent Value Rights Agreement, by and between AcelRx and the Rights Agent (Filed With SEC on May 29, 2020)
- Form of Contingent Value Rights Agreement, by and between AcelRx and the Rights Agent (Filed With SEC on May 27, 2020)
- Form of Contingent Value Rights Agreement, by and between the Parent and the Rights Agent (Filed With SEC on March 16, 2020)
- Co-Promotion Agreement, dated March 15, 2020, by and between the Parent and the Company (Filed With SEC on March 16, 2020)
- Description of Registrants Securities (Filed With SEC on March 12, 2020)
- Payoff Letter, entered into as of August 30, 2019, by and among Tetraphase Pharmaceuticals, Inc., Solar Capital Ltd., as collateral agent and lender, and the other lenders named... (Filed With SEC on August 30, 2019)
- Offer letter, dated as of July 31, 2019, by and between the Registrant and Larry Edwards (Filed With SEC on August 8, 2019)
- Offer letter, dated as of December 27, 2017, by and between the Registrant and Larry Tsai (Filed With SEC on March 6, 2018)
- Amendment, dated as of December 5, 2017, by and between the Registrant and the President and Fellows of Harvard College, as amended (Filed With SEC on March 6, 2018)
- Offer letter, dated as of March 1, 2018, by and between the Registrant and Larry Edwards (Filed With SEC on March 6, 2018)
- Offer Letter, dated as of September 21, 2017, by and between the Registrant and Kamalam Unninayar (Filed With SEC on November 1, 2017)
- - 2 - (Filed With SEC on May 7, 2015)
- SECOND AMENDMENT TO OFFER LETTER (Filed With SEC on May 12, 2014)
- THIRD AMENDMENT TO OFFER LETTER (Filed With SEC on May 12, 2014)
- AMENDMENT TO OFFER LETTER (Filed With SEC on May 12, 2014)
- LEASEAGREEMENT (Filed With SEC on March 6, 2014)
- Additional abbreviations may also be used though not in the above list. (Filed With SEC on March 5, 2013)
- TetraphasePharmaceuticals, Inc. Confidential (Filed With SEC on February 11, 2013)
- Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on February 11, 2013)
- LEASEAGREEMENT (Filed With SEC on February 11, 2013)
- Tetraphase Pharmaceuticals, Inc. Confidential (Filed With SEC on February 11, 2013)
- TETRAPHASE PHARMACEUTICALS, INC. August 10, 2006 (Filed With SEC on February 11, 2013)
- SECOND AMENDED AND RESTATED REGISTRATION RIGHTSAGREEMENT (Filed With SEC on February 11, 2013)
